{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T15:12:19.503839+00:00","company":{"ticker":"INBP","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC"},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"099667fbc62a114f1c1a95695bfbcfa62b1d5054","cik":1016504,"ticker":"INBP","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2026-05-08T23:59:59+00:00","payload":{"eps_text":"$(0.05)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $1.5 million","period_text":"nine months ended March 31, 2026","report_date":"2026-05-08","result_type":"reported_results","revenue_text":"$34.1 million"},"claim":"INTEGRATED BIOPHARMA INC reported nine months ended March 31, 2026 results: revenue $34.1 million, net income net loss of $1.5 million, EPS $(0.05).","evidence_excerpt":"ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%.  The Company had an operating loss for the nine-month period ended","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001437749-26-015928","anchor_url":"https://secwatch.observer/filing/0001437749-26-015928#claim-099667fbc62a114f1c1a95695bfbcfa62b1d5054","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/0001437749-26-015928-index.htm"},{"fact_type":"earnings_release","fact_key":"f12a2b6e7595b51cc6d9edb2f5f53be62ff81984","cik":1016504,"ticker":"INBP","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2026-05-08T23:59:59+00:00","payload":{"eps_text":"$(0.03)","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of $0.8 million","period_text":"quarter ended March 31, 2026","report_date":"2026-05-08","result_type":"reported_results","revenue_text":"$10.1 million"},"claim":"INTEGRATED BIOPHARMA INC reported quarter ended March 31, 2026 results: revenue $10.1 million, net income net loss of $0.8 million, EPS $(0.03).","evidence_excerpt":"BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2026. Revenue for the quarter ended March 31, 2026 was $10.1 million compared to $13.9 million for the quarter ended March 31, 2025, a decrease of $3.8 million or 27.3%.  The Company had an operating loss of $1.1 million in the quarter ended March","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001437749-26-015928","anchor_url":"https://secwatch.observer/filing/0001437749-26-015928#claim-f12a2b6e7595b51cc6d9edb2f5f53be62ff81984","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/0001437749-26-015928-index.htm"},{"fact_type":"earnings_release","fact_key":"ef6d8222cc85cf8f3d5edf3ab939919680396cb3","cik":1016504,"ticker":"INBP","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2024-05-10T23:59:59+00:00","payload":{"eps_text":"$0.01","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$0.3 million","period_text":"quarter ended March 31, 2024","report_date":"2024-05-10","result_type":"reported_results","revenue_text":"$13.1 million"},"claim":"INTEGRATED BIOPHARMA INC reported quarter ended March 31, 2024 results: revenue $13.1 million, net income $0.3 million, EPS $0.01.","evidence_excerpt":"(the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2024. Revenue for each of the quarters ended March 31, 2024 and 2023 were approximately $13.1 million.  The Company had operating income for the quarter ended March 31, 2024 and 2023 of approximately $0.4 million and $44,000, respectively. Revenue for the nine-month period ended","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-016041","anchor_url":"https://secwatch.observer/filing/0001437749-24-016041#claim-ef6d8222cc85cf8f3d5edf3ab939919680396cb3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774924016041/0001437749-24-016041-index.htm"}]}